Palatin Technologies, Inc. (PTN)

Market Cap	26.03M -10.4%
Revenue (ttm)	12.88M +3,581.2%
Net Income	-6.25M
EPS	-3.04
Shares Out	1.78M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,421
Open	14.91
Previous Close	14.41
Day's Range	14.88 - 14.91
52-Week Range	7.25 - 31.00
Beta	-0.09
Analysts	Strong Buy
Price Target	53.50 (+259.54%)
Earnings Date	May 13, 2026

About PTN

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company als...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 28, 1993
• Employees: 29
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: PTN
• Website: https://palatin.com

Analyst Summary

According to 3 analysts, the average rating for PTN stock is "Strong Buy." The 12-month stock price target is $53.5, which is an increase of 259.54% from the latest price.

Price Target

$53.5

(259.54% upside)

Analyst Consensus: Strong Buy